United States Patent 5,525,616: Claim Scope, Expiration, and Patent Landscape for N-Alkyl Deoxynojirimycin Glycolipid Inhibitors

U.S. Patent No. 5,525,616 covers in-vitro inhibition of glycolipid biosynthesis in human cells using N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol, commonly known as N-alkyl deoxynojirimycin derivatives. The broadest claim covers N-alkyl groups containing two to eight carbon atoms. The dependent claims narrow the chemistry to C4-C6 alkyl groups, specifically butyl and hexyl derivatives, and identify concentration and glycolipid-substrate limitations.

The patent is expired. Because it issued on June 11, 1996, and is governed by the pre-URAA 17-year term measured from issue, its ordinary expiration date was June 11, 2013, absent a special adjustment or enforceable terminal-disclaimer issue. It therefore does not create a current U.S. patent barrier to generic development, research use, or commercial manufacture of compounds within the claims. [1]

What does U.S. Patent 5,525,616 protect?

The patent protects a cell-based method, not a composition of matter and not a general therapeutic treatment method.

Claim	Protected subject matter	Scope
1	In-vitro inhibition of glycolipid biosynthesis in human cells using an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol	Broadest claim; N-alkyl group contains C2-C8
2	Claim 1 limited to C4-C6 alkyl groups	Intermediate genus
3	Claim 2 limited to butyl	Species claim
4	Claim 2 limited to hexyl	Species claim
5	Claim 1 limited to an inhibitory concentration of about 50-500 μM	Concentration limitation
6	Claim 1 limited to glucoceramide-based glycosphingolipids	Substrate limitation
7	Claim 1 limited to a lysosomal glycolipid	Functional or cellular-substrate limitation

The independent claim requires all of the following:

Human cells.
Cells capable of producing glycolipids.
An in-vitro setting.
An N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol.
An alkyl group containing two to eight carbon atoms.
A glycolipid-inhibitory effective amount.
Inhibition of glycolipid biosynthesis.

The claim does not cover every use of an N-alkyl deoxynojirimycin derivative. It requires a method directed to glycolipid biosynthesis in human cells under in-vitro conditions.

What chemical compounds fall within the patent claims?

1,5-Dideoxy-1,5-imino-D-glucitol is 1-deoxynojirimycin, commonly abbreviated DNJ. N-alkyl substitution at the imino nitrogen produces compounds including N-butyldeoxynojirimycin and N-hexyldeoxynojirimycin.

Compound class	Relationship to claim 1	Examples
N-methyl DNJ	Outside the literal C2-C8 requirement	C1 alkyl excluded
N-ethyl DNJ	Within claim 1	C2
N-propyl DNJ	Within claim 1	C3
N-butyl DNJ	Within claims 1-3	C4
N-pentyl DNJ	Within claims 1-2	C5
N-hexyl DNJ	Within claims 1, 2 and 4	C6
N-heptyl DNJ	Within claim 1	C7
N-octyl DNJ	Within claim 1	C8
N-nonyl DNJ	Outside the literal claim 1 range	C9

Claim 1 is drafted by carbon-count range rather than by a single named compound. On its face, it includes straight-chain and potentially branched C2-C8 N-alkyl groups unless the specification or prosecution history narrows the term "alkyl." Claim 3, which recites butyl, should ordinarily be read as a narrower species within claim 2. The precise treatment of n-butyl, sec-butyl, isobutyl and tert-butyl would depend on the patent specification, prosecution history and applicable claim-construction principles.

The patent does not expressly require a particular salt, stereoisomeric presentation, formulation, purity level or pharmaceutical dosage form. A compound supplied in a salt form could still implicate the method claim if the active N-alkyl DNJ species is used in the claimed cellular assay or process.

Does the patent cover miglustat or N-butyldeoxynojirimycin?

Yes, the chemistry recited in claims 1 and 3 corresponds to N-butyldeoxynojirimycin, also known as miglustat. Miglustat is an iminosugar that inhibits enzymes involved in glycosphingolipid metabolism. It has been marketed in the United States as Zavesca for certain patients with mild-to-moderate type 1 Gaucher disease and for Niemann-Pick disease type C. [2]

The patent claim, however, is narrower than the commercial drug concept in several important respects:

It requires in-vitro treatment of human cells.
It concerns inhibition of glycolipid biosynthesis.
It does not expressly claim oral administration.
It does not claim treatment of Gaucher disease or Niemann-Pick disease type C.
It does not claim a pharmaceutical composition.
It does not claim a particular dosage regimen.
It does not claim the commercial product label or clinical indication.

A commercial product containing miglustat would not, merely because it contains the claimed compound, necessarily infringe claim 3. Direct infringement would require practice of the claimed method, including the in-vitro cellular limitation. Human administration of miglustat would more naturally be tested against a treatment-of-disease claim, composition claim or formulation claim, none of which appears in the claims provided.

How broad is claim 1?

Claim 1 is chemically broad but operationally narrow.

Its chemical breadth comes from the C2-C8 N-alkyl genus. It can cover multiple N-alkyl DNJ derivatives, including compounds that were not individually named in the claim. Its operational limitation comes from the requirement that the cells be subjected to the compound in vitro.

The phrase "human cells capable of producing glycolipids" is potentially broad because many human cell types synthesize glycolipids. The claim is not limited to hepatocytes, fibroblasts, neurons, macrophages or any particular disease-derived cell line. The phrase "glycolipid inhibitory effective amount" is also functional. It requires an amount that produces the claimed inhibitory effect but does not impose a fixed concentration in claim 1.

Claim 5 adds a narrower numerical range of approximately 50 μM to approximately 500 μM. The use of "about" introduces ordinary approximation flexibility, but the claim would still require a concentration within a range centered on those values. A concentration materially below or above the range may avoid literal infringement of claim 5 while remaining potentially relevant to claim 1.

What glycolipids and pathways are covered?

Claim 6 identifies glucoceramide-based glycosphingolipids. This language points toward glycosphingolipid biosynthesis involving glucosylceramide and downstream glycosphingolipids. Miglustat is associated with inhibition of glucosylceramide synthase and reduction of glycosphingolipid substrate formation, although its pharmacology is concentration- and pathway-dependent. [2]

Claim 7 covers a method in which the glycolipid is a lysosomal glycolipid. That limitation may be relevant to lysosomal storage disease research, including cellular models of Gaucher disease, Niemann-Pick disease type C and related sphingolipid-storage disorders.

The claims do not appear to require:

Accumulation of glycolipid in lysosomes;
A specific lysosomal enzyme deficiency;
A named lysosomal storage disease;
A particular glucosylceramide synthase assay;
A reduction in a specific biomarker;
Rescue of a disease phenotype; or
A therapeutic effect in a patient.

The distinction between "biosynthesis" and downstream lysosomal accumulation matters. A method that only accelerates glycolipid degradation, traffics glycolipid out of lysosomes or reduces storage without inhibiting biosynthesis may not satisfy the claim unless the evidence establishes inhibition of biosynthesis.

How do the dependent claims change infringement risk?

Claims 2 through 7 add narrower limitations and therefore generally have less coverage than claim 1.

Claims 2 through 4: compound identity

Claims 2, 3 and 4 focus the patent on C4-C6 alkyl groups and then on butyl and hexyl species. A program using N-ethyl or N-propyl DNJ could remain within claim 1 but outside claims 2 through 4. A program using N-nonyl DNJ would be outside the literal C2-C8 scope of claim 1, subject to any doctrine-of-equivalents analysis.

Claim 5: concentration

Claim 5 is useful against assays conducted at approximately 50-500 μM. It does not cover all concentrations of a claimed N-alkyl DNJ compound. An assay using 10 μM or 1,000 μM would not literally satisfy the stated range, although it could still fall within claim 1 if it is an inhibitory effective amount.

Claim 6: glucoceramide-based glycosphingolipids

Claim 6 focuses on a defined glycolipid class. A study directed to cholesterol trafficking, protein glycosylation or a non-glycolipid lysosomal substrate may not satisfy this limitation.

Claim 7: lysosomal glycolipids

Claim 7 is directed to lysosomal glycolipid biology. A method involving glycolipids confined to the plasma membrane or endoplasmic reticulum may fall outside claim 7, although it could remain within claim 1.

When did U.S. Patent 5,525,616 expire?

Event	Date or status
U.S. patent issued	June 11, 1996
Governing term framework	Pre-URAA patent term, generally 17 years from issue
Ordinary expiration	June 11, 2013
Current status	Expired
Current enforceability	No ordinary enforceable patent rights

The patent’s expiration eliminates current U.S. infringement exposure based solely on the claims quoted. It also means that a Paragraph IV challenge directed only to this patent would have no practical commercial purpose today. The patent may remain relevant as prior art, as a disclosure of the chemistry and biological activity, or as part of historical freedom-to-operate analysis.

Patent expiration does not remove other possible barriers, including later patents directed to formulations, polymorphs, crystalline forms, manufacturing processes, combination therapies, dosing regimens or separate indications. Those later rights must be analyzed independently.

What was the FDA and Orange Book status of the related drug?

Miglustat received FDA approval as Zavesca under NDA 021829. The FDA-approved uses include treatment of adult patients with mild-to-moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option, and treatment of adult and pediatric patients with Niemann-Pick disease type C. [2]

Regulatory issue	Miglustat status
Active ingredient	Miglustat
Drug class	Iminosugar; substrate-reduction therapy
U.S. brand	Zavesca
Original U.S. approval	2003
Later indication	Niemann-Pick disease type C
FDA pathway for generics	ANDA, subject to applicable exclusivity and listed-patent requirements
Biologic or biosimilar pathway	Not applicable; miglustat is a small molecule
Patent at issue	Expired U.S. Patent No. 5,525,616

Because miglustat is a small molecule, biosimilar risk is not the relevant competitive framework. The relevant competitors are generic ANDA applicants and alternative therapies, including enzyme replacement therapies for Gaucher disease and substrate-reduction products in the broader lysosomal storage disease market.

Orange Book analysis must be conducted against the specific NDA and current FDA listing data. An expired research-use method patent does not itself block an ANDA. Orange Book-listed patents, pediatric exclusivity, orphan-drug exclusivity and regulatory exclusivity are separate questions from the enforceability of Patent 5,525,616. [3]

Were Paragraph IV challenges or patent litigation tied to this patent?

The quoted patent’s expiration makes current Paragraph IV litigation against it immaterial. A Paragraph IV certification is relevant when an applicant seeks approval before expiration of an Orange Book-listed patent. An expired patent cannot ordinarily support a current injunction against an ANDA launch.

The available claim set also creates a weak fit for conventional product litigation because the claims are directed to in-vitro cellular methods. A generic manufacturer selling oral miglustat would not automatically practice the claimed method. A patent holder would need to establish that the accused party performs, induces or contributes to performance of each required method step.

No current litigation consequence can be assigned to Patent 5,525,616 solely from the claims provided. The patent should be treated as an expired historical asset rather than an active U.S. launch blocker.

What patent landscape surrounds miglustat and related iminosugars?

The relevant patent landscape has several layers:

Core compound patents

Early patents on N-substituted DNJ compounds could cover the compound class, synthesis and pharmacological activity. Those rights are generally old and are expected to have expired in the United States. Patent 5,525,616 is one method-focused layer in that historical estate.

Method-of-use patents

Later filings could address treatment of specific lysosomal storage diseases, glycosphingolipid reduction, dosing, patient selection or combinations with enzyme replacement therapy. Such claims would be more commercially relevant than the quoted in-vitro method claims if still unexpired.

Formulation patents

A formulation patent could cover particle size, excipients, modified release, taste masking, oral dosage forms or stability improvements. No formulation limitation appears in the quoted claims.

Manufacturing patents

Process patents could cover preparation of miglustat, stereochemical control, purification, crystallization or salt formation. These rights can create manufacturing risk even when the core compound patent has expired.

Regulatory exclusivity

Orphan-drug exclusivity may have delayed approval of competing products for particular indications, but regulatory exclusivity is distinct from patent term. It does not revive an expired patent or create a permanent product monopoly.

Geographic coverage

U.S. Patent 5,525,616 has no current U.S. enforceability. Foreign counterparts must be assessed separately because patent terms, prosecution outcomes and national-phase claims vary by jurisdiction. Expiration in the United States does not establish expiration in Europe, Japan, Canada or other markets.

How strong is the patent estate based on the quoted claims?

The estate is technically broad in compound selection but weak as a current commercial exclusion right.

Factor	Assessment
Chemical genus	Moderately broad, covering C2-C8 N-alkyl DNJ derivatives
Named species	Narrower protection for butyl and hexyl derivatives
Biological target	Broadly stated glycolipid biosynthesis
Cell limitation	Restrictive because use must be in vitro
Product coverage	None apparent
Human treatment coverage	None apparent
Formulation coverage	None apparent
Manufacturing coverage	None apparent
Current term	Expired
Generic launch relevance	Low
Historical prior-art value	High

For freedom-to-operate, the key conclusion is that Patent 5,525,616 should not be treated as an active barrier to commercial miglustat manufacture or sale in the United States. Its main residual value is evidentiary and historical: it describes the relationship between N-alkyl DNJ chemistry and glycolipid inhibition and may be cited in validity, obviousness, written-description or enablement analyses involving later patents.

What generic launch scenarios exist for miglustat?

A generic miglustat launch would primarily depend on:

FDA approval of an ANDA.
Any remaining Orange Book-listed patents for the relevant NDA.
Orphan-drug or other regulatory exclusivity for the proposed indication.
Commercial supply of active pharmaceutical ingredient.
Manufacturing-process freedom to operate.
Market size and reimbursement economics.
Competition from enzyme replacement and other substrate-reduction therapies.

Patent 5,525,616 does not materially constrain those scenarios because it expired in 2013 and does not claim the commercial product as such. A generic applicant could still face later patents or non-patent barriers, but those risks arise outside the claim set quoted.

Key Takeaways

U.S. Patent 5,525,616 covers in-vitro inhibition of glycolipid biosynthesis in human cells.
Claim 1 covers N-alkyl DNJ derivatives with C2-C8 alkyl groups.
Claims 3 and 4 specifically cover butyl and hexyl derivatives.
Miglustat, or N-butyldeoxynojirimycin, falls within the chemical scope of the claims.
The claims do not expressly cover oral treatment, Gaucher disease, Niemann-Pick disease type C, formulations or manufacturing.
Claim 5 is limited to approximately 50-500 μM.
Claims 6 and 7 focus on glucoceramide-based glycosphingolipids and lysosomal glycolipids.
The patent expired on June 11, 2013, under the ordinary pre-URAA term calculation.
It is not a current U.S. patent barrier to generic miglustat launch.
Current competition is governed by later patents, FDA exclusivity, supply-chain constraints and commercial economics, not by this expired method patent.

FAQs

Is miglustat literally covered by claim 3?

Yes. Miglustat is N-butyldeoxynojirimycin, and claim 3 recites an N-alkyl derivative with a butyl group. The method must still satisfy the in-vitro human-cell and glycolipid-biosynthesis limitations.

Does the patent cover administering miglustat to a patient?

Not based on the claims provided. Claim 1 expressly requires subjecting human cells in vitro to the compound. It does not recite administering the compound to a human or treating a disease.

Does claim 5 cover all miglustat concentrations?

No. Claim 5 is limited to an inhibitory effective amount of about 50-500 μM. Claim 1 is broader because it does not specify that numerical range, but it still requires an inhibitory effective amount and all other claim limitations.

Is this patent relevant to biosimilar competition?

No. Miglustat is a small-molecule drug, so competition proceeds through generic-drug pathways rather than biosimilar pathways. The patent is also expired.

Can the expired patent still affect a later patent application?

Yes. Its disclosure may be relevant as prior art against later claims directed to N-alkyl DNJ compounds, glycolipid inhibition, lysosomal storage disease methods, formulations or manufacturing processes. Expiration eliminates enforcement rights but does not eliminate prior-art relevance.

References

United States Patent and Trademark Office. (1996). U.S. Patent No. 5,525,616, N-alkyl derivatives of 1,5-dideoxy-1,5-imino-D-glucitol. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2023). Zavesca (miglustat) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	148456	⤷ Start Trial
Austria	268598	⤷ Start Trial
Australia	5813898	⤷ Start Trial
Australia	6783294	⤷ Start Trial
Canada	2159988	⤷ Start Trial
Canada	2278507	⤷ Start Trial
Germany	69401658	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,525,616

Summary for Patent: 5,525,616